Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

Curaxis President comments on new Alzheimer's Association report

Curaxis President comments on new Alzheimer's Association report

AFA president issues statement acknowledging former President's contribution to Alzheimer's awareness

AFA president issues statement acknowledging former President's contribution to Alzheimer's awareness

U-M Medical School earns $368.7 million in NIH research funding during federal fiscal year 2010

U-M Medical School earns $368.7 million in NIH research funding during federal fiscal year 2010

Stem cells delivered intranasally improve motor function in Parkinson's disease

Stem cells delivered intranasally improve motor function in Parkinson's disease

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Ceregene initiates enrollment and dosing in CERE-120 Phase 2b trial for Parkinson's disease

Merz introduces new educational website for patients with focal dystonias

Merz introduces new educational website for patients with focal dystonias

Older people with metabolic syndrome may face high risk of developing memory loss

Older people with metabolic syndrome may face high risk of developing memory loss

Study identifies effects of multiple previous concussions on high school students

Study identifies effects of multiple previous concussions on high school students

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

Research identifies potential reversibility of chronic neurologic disability in stroke survivors

Multi-national group of researchers announce launch of International Genomics of Alzheimer's Project

Multi-national group of researchers announce launch of International Genomics of Alzheimer's Project

Higher intake of monounsaturated, polyunsaturated fatty acids reduce risk of mild cognitive impairment

Higher intake of monounsaturated, polyunsaturated fatty acids reduce risk of mild cognitive impairment

Defective nucleoli linked to Parkinson's disease

Defective nucleoli linked to Parkinson's disease

Vanderbilt researchers announce multi-national collaboration on Alzheimer's disease genetics

Vanderbilt researchers announce multi-national collaboration on Alzheimer's disease genetics

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Software can predict future of sports concussion: New research

Software can predict future of sports concussion: New research

Global consortium aims to discover and map all Alzheimer's genes

Global consortium aims to discover and map all Alzheimer's genes

Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease

Positive results from NRM8499 phase I clinical study in patients with Alzheimer's disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.